Clinical hurdles for curcumin and piperine nanoparticles in prostate cancer treatment. a bridge too far or a path to clinical reality?
Loading...
Authors
Author (Corporation)
Publication date
2026
Type of student thesis
Course of study
Collections
Type
01A - Journal article
Editors
Editor (Corporation)
Supervisor
Parent work
Expert Opinion on Drug Delivery
Special issue
DOI of the original publication
Link
Related research data
Series
Series number
Volume
Issue / Number
Pages / Duration
Patent number
Publisher / Publishing institution
Taylor & Francis
Place of publication / Event location
Edition
Version
Programming language
Assignee
Practice partner / Client
Abstract
While nano-encapsulation enhances the therapeutic index of curcumin, clinical translation remains stalled by a reliance on passive targeting and insufficient manufacturing scalability. Future success depends on shifting from 'beaker' synthesis to microfluidic production (Quality by Design) and adopting active targeting (e.g. PSMA-directed delivery) to penetrate the prostate stroma. Without these strategic pivots and biomarker-driven trials, CPNs risk remaining an academic curiosity rather than evolving into a viable clinical intervention.
Keywords
Subject (DDC)
Event
Exhibition start date
Exhibition end date
Conference start date
Conference end date
Date of the last check
ISBN
ISSN
1742-5247
1744-7593
1744-7593
Language
English
Created during FHNW affiliation
Yes
Strategic action fields FHNW
Publication status
Published
Review
peer-reviewed
Open access category
Hybrid
License
Citation
Yakubu, J., Tagit, O., & Pandey, A. V. (2026). Clinical hurdles for curcumin and piperine nanoparticles in prostate cancer treatment. a bridge too far or a path to clinical reality? Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2026.2619094